Match!
Michael J. Pishvaian
Johns Hopkins University School of Medicine
OncologyChemotherapyFOLFIRINOXFOLFOXChemotherapy regimenIdelalisibPancreatic cancerGemcitabineMetastatic Pancreatic AdenocarcinomaMedicine
3Publications
0Citations
What is this?
Publications 3
Newest
#1Benjamin A. Weinberg (GUMC: Georgetown University Medical Center)H-Index: 7
#2Hongkun Wang (GUMC: Georgetown University Medical Center)H-Index: 23
Last. Michael J. Pishvaian (JHUSOM: Johns Hopkins University School of Medicine)
view all 8 authors...
Source
#1Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 10
#2Michael J. Pishvaian (JHUSOM: Johns Hopkins University School of Medicine)
view all 5 authors...
LESSONS LEARNED Although this study of idelalisib in patients with PDAC was limited in size and duration because of early termination, idelalisib exposure resulted in an overall safety profile consistent with studies in hematological malignancies, except that the incidences of diarrhea and colitis were reduced in patients with PDAC. Preclinical studies of the PI3K pathway in PDAC and positive clinical results of PI3K inhibition in other cancers support the continued development of PI3K inhibitor...
Source
#1Yunes Doleh (AstraZeneca)H-Index: 1
Last. Michael J. Pishvaian (JHUSOM: Johns Hopkins University School of Medicine)
view all 5 authors...
BACKGROUND: Pancreatic cancer represents the third leading cause of US cancer deaths, with median survival /=18 years, with continuous 6-month preindex enrollment. Patients were excluded by resectable disease, another primary cancer, or pregnancy. Cohorts were based on first-line (LOT1) chemotherapy regimen. RESULTS: Overall, 12 978 patients (mean age 70 years, 51% male) were included, among which 5610 (43%) received chemotherapy. Of those, 23% received gemcitabine monotherapy, 22% gemcitabine-n...
Source
1